Accelerated phase chronic myelogenous leukemia

Accelerated phase chronic myelogenous leukemia
SpecialtyHematology and oncology

Accelerated phase chronic myelogenous leukemia is a phase of chronic myelogenous leukemia in which the disease is progressing.It is characterized by an increase in blast cells in the blood and bone marrow, driven by the constitutively active tyrosine kinase produced by the Philadelphia chromosome (BCR-ABL1 gene fusion).[1][2]

Symptoms

Common symptoms include fever, bone pain, and swollen spleen.[3]

Treatment

Patients treated with imatinib, dasatinib, and nilotinib have shown meaningful rates of hematologic and cytogenetic response.[4]

Prognosis

Prognosis is very poor once chronic myelogenous leukemia reaches the accelerated phase; it behaves similarly to acute myeloid leukemia.

References

  1. ↑ Cite error: The named reference Talpaz2002 was invoked but never defined (see the help page).
  2. ↑ Moshe Talpaz (2002). "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study". Blood. 99 (6): 1928–1937. doi:10.1182/blood.v99.6.1928. PMID 11877262. S2CID 29480569.
  3. ↑ "Chronic myelogenous leukemia (CML)".
  4. ↑ Shah, NP (Mar 2008). "Advanced CML: therapeutic options for patients in accelerated and blast phases". Journal of the National Comprehensive Cancer Network. 6 Suppl 2: S31–S36. PMID 18397679.

}}

This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.